UK consults on value based pricing system
This article was originally published in SRA
The UK department of health has released for consultation its plans for introducing a value-based pricing system to determine how much it will pay for new medicines1,2. The plan focuses on determining maximum prices or thresholds for medicines that will reflect the different values that different treatments offer. The proposals also touch on the role that the National Institute for health and Clinical Excellence will play3,4.
You may also be interested in...
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.